SCHEMBL2912579

SCHEMBL2912579

CCOC(=O)Nc1cc(Nc2ncc3ccc(F)c(C)c3n2)cc2c1ncn2C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
JAK3 P52333 2/20 0.35
P2RX3 P56373 1/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
KCNQ4 P56696 1/20 0.35
KCNQ5 Q9NR82 1/20 0.35
KIT P10721 1/20 0.35
SYK P43405 3/20 0.34
USP2 O75604 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
BRAF P15056 1/20 0.33
EGFR P00533 1/20 0.33
CDK2 P24941 2/20 0.33
CDK9 P50750 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2920899 0.86 ALDH1A1 (0.39) ALDH1A1HPGDJAK2JAK1JAK3
SCHEMBL2920702 0.82 BRAF (0.38) P2RX3KCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL2918651 0.79 KIT (0.38) ALDH1A1JAK2JAK1JAK3KCNQ3
SCHEMBL2917497 0.79 JAK2 (0.35) JAK2JAK1JAK3SYKEGFR
SCHEMBL13175537 0.72 KIT (0.39) ALDH1A1JAK2JAK1JAK3KIT
SCHEMBL2919936 0.71 ALDH1A1 (0.45) ALDH1A1HPGDKCNQ3KCNQ2KCNQ4
SCHEMBL13057482 0.69 CYP1A2 (0.44) ALDH1A1HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL2913576 0.68 EGFR (0.40) ALDH1A1JAK2JAK1JAK3KIT
SCHEMBL2916257 0.67 AKR1B1 (0.44) ALDH1A1HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL2919023 0.67 KIT (0.40) ALDH1A1HPGDJAK2JAK3KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K ALDH1A1 4359/4885HPGD 3655/4885JAK2 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.